3 stocks trading at 52-week lows I’d buy today

Rupert Hargreaves looks at three companies he believes have been wrongly oversold by investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The recent market volatility has thrown up some fantastic bargains for investors. So, without further ado, here are three companies trading at 52-week lows that I’m considering buying today.

Missed expectations

Year-to-date, shares in medical products company Convatec (LSE: CTEC) have lost 21%. Investors have rushed for the exit following a series of worrying developments including a profit warning and immediate departure of its CEO a few weeks ago.

However, over the longer term, I believe this business should be able to rebuild its reputation because the demand for wound care products is only going to expand. Analysts are predicting sector growth of around 4% per annum.

These tailwinds should give Convatec room to stabilise itself in the years ahead. City analysts are expecting earnings per share (EPS) to come in at $0.16 for 2018, putting the shares on a forward PE of 12.9. In my view, this isn’t too demanding, especially for a defensive healthcare company.

Looking past Convatec’s short-term, self-inflicted issues, I think now could be a good time to snap up shares in the troubled medical group.

Growing market

I’m optimistic about the outlook for security group G4S (LSE: GFS) for similar reasons. The company’s problems are mainly self-inflicted, and the broader global security market is expected to grow at a high single-digit annual rate for the foreseeable future. 

As one of the largest private security firms in Europe, with a foothold in the United States and other regions around the world, G4S is well-placed to benefit from this growth.

Recently, shares in the firm have come under pressure after the UK government was forced to take control of Birmingham prison, which it has been running since 2011 on a 15-year contract. This is just a small part of the group’s global operation, but it seems investors are worried about the impact the development will have on the company’s reputation.

While it’s not ideal, I still think the shares are attractive, primarily because they are changing hands at a highly-discounted 10.6 times forward earnings, and support a dividend yield of 5%. After G4S sorts out its problems, I reckon the shares could re-rate to a higher multiple.

Brexit jitters

My last 52-week low pick is recruiter Hays (LSE: HAS). After adding around 15% during the first eight months of 2018, shares in Hays are now trading down 20% on the year after issuing a weak trading update at the beginning of October.

I think this could be an excellent opportunity for value-seeking investors. The sell-off has taken the shares down to a valuation of just 12.5 times forward earnings. Previously, the stock was trading at a forward P/E of nearly 20, which tells me that recent decline seems to be based on Hays’ premium valuation more than anything else. Indeed, City analysts are still expecting EPS growth of 11% for fiscal 2019. Further growth could be on the cards in the years after as well, as the global economy continues to expand. 

Added to the attractive valuation, there’s a 4.5% dividend yield on offer, backed up by £80m of net cash on the balance sheet.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »